Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial.
Lancet., Jul;378(9787):229-37 (2011)
Successful HIV treatment: lessons learned.
J Manag Care Pharm., Sep;12(7 Suppl B):S6-11 (2006)
Pilot study of a novel short-cycle antiretroviral treatment interruption strategy: 48-week results of the five-days-on, two-days-off (FOTO) study.
HIV Clin Trials., 8(1):19-23 (2007)
Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial.
AIDS., Jan;23(3):423-6 (2009)
Tai Chi for osteopenic women: design and rationale of a pragmatic randomized controlled trial.
BMC Musculoskelet Disord., 11:40 (2010)
A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy.
AIDS., Mar;16(4):579-88 (2002)
Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimen.
J. Acquir. Immune Defic. Syndr., Sep;37(1):1140-6 (2004)
Impact of Tai Chi exercise on multiple fracture-related risk factors in post-menopausal osteopenic women: a pilot pragmatic, randomized trial.
BMC Complement Altern Med., 12:7 (2012)
Efficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naive HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE Trials.
J. Acquir. Immune Defic. Syndr., May;60(1):33-42 (2012)
Relationship between plasma protease inhibitor concentrations and lipid elevations in HIV patients on a double-boosted protease inhibitor regimen (saquinavir/lopinavir/ritonavir).
J Clin Pharmacol., Apr;50(4):392-400 (2010)
Prophylaxis for human immunodeficiency virus-related Pneumocystis carinii pneumonia: using simulation modeling to inform clinical guidelines.
Arch. Intern. Med., Apr;162(8):921-8 (2002)
Pediatrics in an inner city environment: a practice responds to the challenges of the 1990s.
J Ambul Care Manage., Jan;16(1):42-8 (1993)
Primary prophylaxis for Pneumocystis carinii pneumonia in HIV-infected people with CD4 counts below 200/mm3: a cost-effectiveness analysis.
J. Acquir. Immune Defic. Syndr., 4(5):521-31 (1991)
The coxsackievirus and adenovirus receptor is a transmembrane component of the tight junction.
Proc. Natl. Acad. Sci. U.S.A., Dec;98(26):15191-6 (2001)
CD4+ count-guided interruption of antiretroviral treatment.
N. Engl. J. Med., Nov;355(22):2283-96 (2006)
Risk for opportunistic disease and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic therapy: a randomized trial.
Ann. Intern. Med., Sep;149(5):289-99 (2008)
Treatment problems in endometrial cancer.
Clin Obstet Gynecol., Sep;10(3):625-40 (1967)
Leukocyte migration enhancement as an indicator of immunologic enhancement. I. Pregnancy.
Am. J. Obstet. Gynecol., Jan;136(1):1-4 (1980)
Feasibility of intraoperative administration of chemotherapy for gynecologic malignancies: assessment of acute postoperative morbidity.
Gynecol. Oncol., Feb;48(2):227-31 (1993)
Prophylaxis for disseminated Mycobacterium avium complex (MAC) infection in patients with AIDS: a cost-effectiveness analysis.
J. Acquir. Immune Defic. Syndr. Hum. Retrovirol., Aug;15(4):275-82 (1997)